{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:43:17Z","timestamp":1794609797361,"version":"4.9.1"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00296-021-04819-1","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T17:02:42Z","timestamp":1616864562000},"page":"1021-1036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-0999","authenticated-orcid":false,"given":"Pankti","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-2990","authenticated-orcid":false,"given":"Latika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"key":"4819_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347. https:\/\/doi.org\/10.1056\/NEJM197502132920706","journal-title":"N Engl J Med"},{"key":"4819_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292:403\u2013407. https:\/\/doi.org\/10.1056\/NEJM197502202920807","journal-title":"N Engl J Med"},{"key":"4819_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nature reviews. Rheumatology 14:290\u2013302. https:\/\/doi.org\/10.1038\/nrrheum.2018.56","journal-title":"Rheumatology"},{"key":"4819_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge Z, Tansley S, Shaddick G et al (2019) Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 101:48\u201355. https:\/\/doi.org\/10.1016\/j.jaut.2019.04.001","journal-title":"J Autoimmun"},{"key":"4819_CR5","doi-asserted-by":"publisher","first-page":"e0154285","DOI":"10.1371\/journal.pone.0154285","volume":"11","author":"S Sato","year":"2016","unstructured":"Sato S, Murakami A, Kuwajima A et al (2016) Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS ONE 11:e0154285. https:\/\/doi.org\/10.1371\/journal.pone.0154285","journal-title":"PLoS ONE"},{"key":"4819_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/nan.12528","volume":"45","author":"SA Yasin","year":"2019","unstructured":"Yasin SA, Schutz PW, Deakin CT et al (2019) Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathol Appl Neurobiol 45:495\u2013512. https:\/\/doi.org\/10.1111\/nan.12528","journal-title":"Neuropathol Appl Neurobiol"},{"key":"4819_CR7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","volume":"54","author":"N Kobayashi","year":"2015","unstructured":"Kobayashi N, Takezaki S, Kobayashi I et al (2015) Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology 54:784\u2013791. https:\/\/doi.org\/10.1093\/rheumatology\/keu385","journal-title":"Rheumatology"},{"key":"4819_CR8","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52:1571\u20131576. https:\/\/doi.org\/10.1002\/art.21023","journal-title":"Arthritis Rheum"},{"key":"4819_CR9","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/acr.21985","volume":"65","author":"Z Chen","year":"2013","unstructured":"Chen Z, Cao M, Plana MN et al (2013) Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res 65:1316\u20131324. https:\/\/doi.org\/10.1002\/acr.21985","journal-title":"Arthritis Care Res"},{"key":"4819_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","volume":"78","author":"DJB Kurtzman","year":"2018","unstructured":"Kurtzman DJB, Vleugels RA (2018) Anti-melanoma differentiation\u2013associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol 78:776\u2013785. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.010","journal-title":"J Am Acad Dermatol"},{"key":"4819_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11926-018-0798-1","volume":"20","author":"S Moghadam-Kia","year":"2018","unstructured":"Moghadam-Kia S, Oddis CV, Aggarwal R (2018) Anti-MDA5 antibody spectrum in western world. Curr Rheumatol Rep 20:78. https:\/\/doi.org\/10.1007\/s11926-018-0798-1","journal-title":"Curr Rheumatol Rep"},{"key":"4819_CR12","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"4819_CR13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3389\/fimmu.2019.00848","volume":"10","author":"M Mahler","year":"2019","unstructured":"Mahler M, Betteridge Z, Bentow C et al (2019) Comparison of three immunoassays for the detection of myositis specific antibodies. Front Immunol 10:848. https:\/\/doi.org\/10.3389\/fimmu.2019.00848","journal-title":"Front Immunol"},{"key":"4819_CR14","first-page":"204","volume":"30","author":"K Tokiyama","year":"1990","unstructured":"Tokiyama K, Tagawa H, Yokota E et al (1990) Two cases of amyopathic dermatomyositis with fatal rapidly progressive interstitial pneumonitis. Ryumachi [Rheumatism] 30:204\u2013209 (discussion 209\u2013211)","journal-title":"Ryumachi [Rheumatism]"},{"key":"4819_CR15","first-page":"705","volume":"40","author":"Y Nanke","year":"2000","unstructured":"Nanke Y, Tateisi M, Yamagata H et al (2000) A case of amyopathic dermatomyositis with rapidly progressive interstitial pneumonia. Ryumachi [Rheumatism] 40:705\u2013710","journal-title":"Ryumachi [Rheumatism]"},{"key":"4819_CR16","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato S, Hoshino K, Satoh T et al (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 60:2193\u20132200. https:\/\/doi.org\/10.1002\/art.24621","journal-title":"Arthritis Rheum"},{"key":"4819_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1073\/pnas.022637199","volume":"99","author":"D Kang","year":"2002","unstructured":"Kang D, Gopalkrishnan RV, Wu Q et al (2002) mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci USA 99:637\u2013642. https:\/\/doi.org\/10.1073\/pnas.022637199","journal-title":"Proc Natl Acad Sci USA"},{"key":"4819_CR18","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/acr.21985","volume":"65","author":"Z Chen","year":"2013","unstructured":"Chen Z, Cao M, Plana MN et al (2013) Utility of anti-melanoma differentiation\u2013associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res 65:1316\u20131324. https:\/\/doi.org\/10.1002\/acr.21985","journal-title":"Arthritis Care Res"},{"key":"4819_CR19","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/art.1780291109","volume":"29","author":"ML Christensen","year":"1986","unstructured":"Christensen ML, Pachman LM, Schneiderman R et al (1986) Prevalence of coxsackie b virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum 29:1365\u20131370. https:\/\/doi.org\/10.1002\/art.1780291109","journal-title":"Arthritis Rheum"},{"key":"4819_CR20","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/rheumatology\/39.9.1037","volume":"39","author":"G Chevrel","year":"2000","unstructured":"Chevrel G, Calvet A, Belin V, Miossec P (2000) Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology 39:1037\u20131039. https:\/\/doi.org\/10.1093\/rheumatology\/39.9.1037","journal-title":"Rheumatology"},{"key":"4819_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","volume":"49","author":"R Nakashima","year":"2010","unstructured":"Nakashima R, Imura Y, Kobayashi S et al (2010) The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 49:433\u2013440. https:\/\/doi.org\/10.1093\/rheumatology\/kep375","journal-title":"Rheumatology"},{"key":"4819_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tim.2018.08.007","volume":"27","author":"AG Dias Junior","year":"2019","unstructured":"Dias Junior AG, Sampaio NG, Rehwinkel J (2019) A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol 27:75\u201385. https:\/\/doi.org\/10.1016\/j.tim.2018.08.007","journal-title":"Trends Microbiol"},{"key":"4819_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjd.14882","volume":"176","author":"T Matsushita","year":"2017","unstructured":"Matsushita T, Mizumaki K, Kano M et al (2017) Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol 176:395\u2013402. https:\/\/doi.org\/10.1111\/bjd.14882","journal-title":"Br J Dermatol"},{"key":"4819_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218594","author":"Y Wang","year":"2020","unstructured":"Wang Y, Du G, Zhang G et al (2020) Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218594","journal-title":"Ann Rheum Dis"},{"key":"4819_CR25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01618-2020","author":"M Giannini","year":"2020","unstructured":"Giannini M, Ohana M, Nespola B et al (2020) Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01618-2020","journal-title":"Eur Respir J"},{"key":"4819_CR26","doi-asserted-by":"publisher","first-page":"102666","DOI":"10.1016\/j.autrev.2020.102666","volume":"19","author":"E De Lorenzis","year":"2020","unstructured":"De Lorenzis E, Natalello G, Gigante L et al (2020) What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19? Autoimmun Rev 19:102666. https:\/\/doi.org\/10.1016\/j.autrev.2020.102666","journal-title":"Autoimmun Rev"},{"key":"4819_CR27","unstructured":"Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans\u2014The Lancet Respiratory Medicine. https:\/\/www.thelancet.com\/journals\/lanres\/article\/PIIS2213-2600(20)30243-5\/fulltext. Accessed 12 Nov 2020"},{"key":"4819_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/BOR.0000000000000749","volume":"32","author":"L Gupta","year":"2020","unstructured":"Gupta L, Chinoy H (2020) Monitoring disease activity and damage in adult and juvenile idiopathic inflammatory myopathy. Curr Opin Rheumatol 32:553\u2013561. https:\/\/doi.org\/10.1097\/BOR.0000000000000749","journal-title":"Curr Opin Rheumatol"},{"key":"4819_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217953","author":"L Gupta","year":"2020","unstructured":"Gupta L, Misra DP, Agarwal V et al (2020) Response to: \u2018telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort\u2019 by Costa et al. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217953","journal-title":"Ann Rheum Dis"},{"key":"4819_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04737-8","author":"R Naveen","year":"2020","unstructured":"Naveen R, Sundaram TG, Agarwal V, Gupta L (2020) Teleconsultation experience with the idiopathic inflammatory myopathies: a prospective observational cohort study during the COVID-19 pandemic. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-020-04737-8","journal-title":"Rheumatol Int"},{"key":"4819_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa610","author":"L Gupta","year":"2020","unstructured":"Gupta L, Lilleker JB, Agarwal V et al (2020) COVID-19 and myositis\u2014unique challenges for patients. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keaa610","journal-title":"Rheumatology"},{"key":"4819_CR32","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1002\/art.34657","volume":"64","author":"T Gono","year":"2012","unstructured":"Gono T, Kawaguchi Y, Kuwana M et al (2012) Brief report: association of HLA-DRB1*0101\/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 64:3736\u20133740. https:\/\/doi.org\/10.1002\/art.34657","journal-title":"Arthritis Rheum"},{"key":"4819_CR33","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3899\/jrheum.170165","volume":"44","author":"Z Chen","year":"2017","unstructured":"Chen Z, Wang Y, Kuwana M et al (2017) HLA-DRB1 alleles as genetic risk factors for the development of anti-MDA5 antibodies in patients with dermatomyositis. J Rheumatol 44:1389\u20131393. https:\/\/doi.org\/10.3899\/jrheum.170165","journal-title":"J Rheumatol"},{"key":"4819_CR34","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","volume":"78","author":"S Rothwell","year":"2019","unstructured":"Rothwell S, Chinoy H, Lamb JA et al (2019) Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis 78:996\u20131002. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215046","journal-title":"Ann Rheum Dis"},{"key":"4819_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/annrheumdis-2017-212149","volume":"77","author":"Y Kochi","year":"2018","unstructured":"Kochi Y, Kamatani Y, Kondo Y et al (2018) Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis 77:602\u2013611. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212149","journal-title":"Ann Rheum Dis"},{"key":"4819_CR36","doi-asserted-by":"publisher","first-page":"R214","DOI":"10.1186\/ar3547","volume":"13","author":"Y Muro","year":"2011","unstructured":"Muro Y, Sugiura K, Hoshino K et al (2011) Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther 13:R214. https:\/\/doi.org\/10.1186\/ar3547","journal-title":"Arthritis Res Ther"},{"key":"4819_CR37","doi-asserted-by":"publisher","first-page":"e001202","DOI":"10.1136\/rmdopen-2020-001202","volume":"6","author":"N Nishina","year":"2020","unstructured":"Nishina N, Sato S, Masui K et al (2020) Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open 6:e001202. https:\/\/doi.org\/10.1136\/rmdopen-2020-001202","journal-title":"RMD Open"},{"key":"4819_CR38","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/j.1365-2133.2012.11145.x","volume":"167","author":"WC Sun","year":"2012","unstructured":"Sun WC, Sun YC, Lin H et al (2012) Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Br J Dermatol 167:1236\u20131244. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11145.x","journal-title":"Br J Dermatol"},{"key":"4819_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05339-2","author":"J Bai","year":"2020","unstructured":"Bai J, Wu C, Zhong D et al (2020) Hierarchical cluster analysis of cytokine profiles reveals a cutaneous vasculitis-associated subgroup in dermatomyositis. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-020-05339-2","journal-title":"Clin Rheumatol"},{"key":"4819_CR40","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/rheumatology\/kez525","volume":"59","author":"I Melki","year":"2020","unstructured":"Melki I, Devilliers H, Gitiaux C et al (2020) Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-\u03b1 signalling. Rheumatology 59:1927\u20131937. https:\/\/doi.org\/10.1093\/rheumatology\/kez525","journal-title":"Rheumatology"},{"key":"4819_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13075-020-02160-9","volume":"22","author":"H Kim","year":"2020","unstructured":"Kim H, Gunter-Rahman F, McGrath JA et al (2020) Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther 22:69. https:\/\/doi.org\/10.1186\/s13075-020-02160-9","journal-title":"Arthritis Res Ther"},{"key":"4819_CR42","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1172\/JCI129301","volume":"130","author":"AA de Jesus","year":"2020","unstructured":"de Jesus AA, Hou Y, Brooks S et al (2020) Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest 130:1669\u20131682. https:\/\/doi.org\/10.1172\/JCI129301","journal-title":"J Clin Invest"},{"key":"4819_CR43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S (2019) Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381:291\u2013293. https:\/\/doi.org\/10.1056\/NEJMc1900045","journal-title":"N Engl J Med"},{"key":"4819_CR44","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","volume":"51","author":"T Koga","year":"2012","unstructured":"Koga T, Fujikawa K, Horai Y et al (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 51:1278\u20131284. https:\/\/doi.org\/10.1093\/rheumatology\/ker518","journal-title":"Rheumatology"},{"key":"4819_CR45","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","volume":"49","author":"T Gono","year":"2010","unstructured":"Gono T, Kawaguchi Y, Satoh T et al (2010) Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 49:1713\u20131719. https:\/\/doi.org\/10.1093\/rheumatology\/keq149","journal-title":"Rheumatology"},{"key":"4819_CR46","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/acr.21992","volume":"65","author":"JC Hall","year":"2013","unstructured":"Hall JC, Casciola-Rosen L, Samedy L-A et al (2013) Anti-melanoma differentiation\u2013associated protein 5\u2013associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res 65:1307\u20131315. https:\/\/doi.org\/10.1002\/acr.21992","journal-title":"Arthritis Care Res"},{"issue":"6","key":"4819_CR47","first-page":"891","volume":"32","author":"A Ceribelli","year":"2014","unstructured":"Ceribelli A, Fredi M, Taraborelli M et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis. Clin Exp Rheumatol 32(6):891\u2013897","journal-title":"Clin Exp Rheumatol"},{"key":"4819_CR48","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.jtauto.2019.100013","volume":"2","author":"ACM Platteel","year":"2019","unstructured":"Platteel ACM, Wevers BA, Lim J et al (2019) Frequencies and clinical associations of myositis-related antibodies in The Netherlands: a one-year survey of all Dutch patients. J Transl Autoimmun 2:100013. https:\/\/doi.org\/10.1016\/j.jtauto.2019.100013","journal-title":"J Transl Autoimmun"},{"key":"4819_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3899\/jrheum.160682","volume":"44","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia S, Oddis CV, Sato S et al (2017) Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in north American patients with dermatomyositis. J Rheumatol 44:319\u2013325. https:\/\/doi.org\/10.3899\/jrheum.160682","journal-title":"J Rheumatol"},{"key":"4819_CR50","doi-asserted-by":"publisher","first-page":"290797","DOI":"10.1155\/2014\/290797","volume":"2014","author":"M Labrador-Horrillo","year":"2014","unstructured":"Labrador-Horrillo M, Martinez MA, Selva-O\u2019Callaghan A et al (2014) Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014:290797. https:\/\/doi.org\/10.1155\/2014\/290797","journal-title":"J Immunol Res"},{"key":"4819_CR51","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Uzunhan Y, Toquet S et al (2020) Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology 95:e70\u2013e78. https:\/\/doi.org\/10.1212\/WNL.0000000000009727","journal-title":"Neurology"},{"key":"4819_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J et al (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65:25\u201334. https:\/\/doi.org\/10.1016\/j.jaad.2010.09.016","journal-title":"J Am Acad Dermatol"},{"key":"4819_CR53","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/acr.22498","volume":"67","author":"NS Narang","year":"2015","unstructured":"Narang NS, Casciola-Rosen L, Li S et al (2015) Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res 67:667\u2013672. https:\/\/doi.org\/10.1002\/acr.22498","journal-title":"Arthritis Care Res"},{"key":"4819_CR54","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/acr.21728","volume":"64","author":"H Cao","year":"2012","unstructured":"Cao H, Pan M, Kang Y et al (2012) Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res 64:1602\u20131610. https:\/\/doi.org\/10.1002\/acr.21728","journal-title":"Arthritis Care Res"},{"key":"4819_CR55","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/rheumatology\/keaa033","volume":"59","author":"N Ono","year":"2020","unstructured":"Ono N, Kai K, Maruyama A et al (2020) The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology 59:918. https:\/\/doi.org\/10.1093\/rheumatology\/keaa033","journal-title":"Rheumatology"},{"key":"4819_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa821","author":"U Rathore","year":"2020","unstructured":"Rathore U, Haldule S, Gupta L (2020) Psoriasiform rashes as the first manifestation of anti-MDA5 associated myositis. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keaa821","journal-title":"Rheumatology"},{"key":"4819_CR57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/03009740802687455","volume":"38","author":"K Fujikawa","year":"2009","unstructured":"Fujikawa K, Kawakami A, Kaji K et al (2009) Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155\/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 38:263\u2013267. https:\/\/doi.org\/10.1080\/03009740802687455","journal-title":"Scand J Rheumatol"},{"key":"4819_CR58","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/1471-2474-11-223","volume":"11","author":"EH Kang","year":"2010","unstructured":"Kang EH, Nakashima R, Mimori T et al (2010) Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 11:223. https:\/\/doi.org\/10.1186\/1471-2474-11-223","journal-title":"BMC Musculoskelet Disord"},{"key":"4819_CR59","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.3892\/ol.2018.9409","volume":"16","author":"Y Liu","year":"2018","unstructured":"Liu Y, Xu L, Wu H et al (2018) Characteristics and predictors of malignancy in dermatomyositis: analysis of 239 patients from northern China. Oncol Lett 16:5960\u20135968. https:\/\/doi.org\/10.3892\/ol.2018.9409","journal-title":"Oncol Lett"},{"key":"4819_CR60","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","volume":"49","author":"K Hoshino","year":"2010","unstructured":"Hoshino K, Muro Y, Sugiura K et al (2010) Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology 49:1726\u20131733. https:\/\/doi.org\/10.1093\/rheumatology\/keq153","journal-title":"Rheumatology"},{"key":"4819_CR61","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","volume":"78","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Pinal-Fernandez I, Kishi T et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78:988\u2013995. https:\/\/doi.org\/10.1136\/annrheumdis-2018-215004","journal-title":"Ann Rheum Dis"},{"key":"4819_CR62","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","volume":"158","author":"I Kobayashi","year":"2011","unstructured":"Kobayashi I, Okura Y, Yamada M et al (2011) Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatri 158:675\u2013677. https:\/\/doi.org\/10.1016\/j.jpeds.2010.11.033","journal-title":"J Pediatri"},{"key":"4819_CR63","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1080\/14397595.2018.1511025","volume":"29","author":"N Iwata","year":"2019","unstructured":"Iwata N, Nakaseko H, Kohagura T et al (2019) Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: experience at a single center in Japan. Mod Rheumatol 29:802\u2013807. https:\/\/doi.org\/10.1080\/14397595.2018.1511025","journal-title":"Mod Rheumatol"},{"key":"4819_CR64","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00296-017-3707-4","volume":"37","author":"A Hussain","year":"2017","unstructured":"Hussain A, Rawat A, Jindal AK et al (2017) Autoantibodies in children with juvenile dermatomyositis: a single centre experience from north-west India. Rheumatol Int 37:807\u2013812. https:\/\/doi.org\/10.1007\/s00296-017-3707-4","journal-title":"Rheumatol Int"},{"key":"4819_CR65","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s10067-019-04918-2","volume":"39","author":"M Zhou","year":"2020","unstructured":"Zhou M, Ye Y, Yan N et al (2020) Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis. Clin Rheumatol 39:1919\u20131927. https:\/\/doi.org\/10.1007\/s10067-019-04918-2","journal-title":"Clin Rheumatol"},{"key":"4819_CR66","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1007\/s10067-019-04729-5","volume":"38","author":"K Yamaguchi","year":"2019","unstructured":"Yamaguchi K, Yamaguchi A, Itai M et al (2019) Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol 38:3443\u20133450. https:\/\/doi.org\/10.1007\/s10067-019-04729-5","journal-title":"Clin Rheumatol"},{"key":"4819_CR67","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10067-015-3001-3","volume":"35","author":"X Ma","year":"2016","unstructured":"Ma X, Chen Z, Hu W et al (2016) Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol 35:489\u2013493. https:\/\/doi.org\/10.1007\/s10067-015-3001-3","journal-title":"Clin Rheumatol"},{"key":"4819_CR68","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00296-020-04590-9","volume":"40","author":"D Kishida","year":"2020","unstructured":"Kishida D, Sakaguchi N, Ueno K et al (2020) Macrophage activation syndrome in adult dermatomyositis: a case-based review. Rheumatol Int 40:1151\u20131162. https:\/\/doi.org\/10.1007\/s00296-020-04590-9","journal-title":"Rheumatol Int"},{"key":"4819_CR69","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/03009742.2019.1653493","volume":"49","author":"M Honda","year":"2020","unstructured":"Honda M, Moriyama M, Kondo M et al (2020) Three cases of autoimmune-associated haemophagocytic syndrome in dermatomyositis with anti-MDA5 autoantibody. Scand J Rheumatol 49:244\u2013246. https:\/\/doi.org\/10.1080\/03009742.2019.1653493","journal-title":"Scand J Rheumatol"},{"key":"4819_CR70","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00296-020-04695-1","volume":"40","author":"L Gupta","year":"2020","unstructured":"Gupta L, Muhammed H, Naveen R et al (2020) Insights into the knowledge, attitude and practices for the treatment of idiopathic inflammatory myopathy from a cross-sectional cohort survey of physicians. Rheumatol Int 40:2047\u20132055. https:\/\/doi.org\/10.1007\/s00296-020-04695-1","journal-title":"Rheumatol Int"},{"key":"4819_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-018-0433-3","author":"C Vuillard","year":"2018","unstructured":"Vuillard C, Pineton de Chambrun M, de Prost N et al (2018) Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study. Ann Intensive Care. https:\/\/doi.org\/10.1186\/s13613-018-0433-3","journal-title":"Ann Intensive Care"},{"key":"4819_CR72","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/14397595.2018.1452179","volume":"29","author":"T Gono","year":"2019","unstructured":"Gono T, Okazaki Y, Murakami A, Kuwana M (2019) Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody. Mod Rheumatol 29:140\u2013145. https:\/\/doi.org\/10.1080\/14397595.2018.1452179","journal-title":"Mod Rheumatol"},{"key":"4819_CR73","doi-asserted-by":"publisher","first-page":"106134","DOI":"10.1016\/j.rmed.2020.106134","volume":"172","author":"X Xing","year":"2020","unstructured":"Xing X, Li A, Li C (2020) Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med 172:106134. https:\/\/doi.org\/10.1016\/j.rmed.2020.106134","journal-title":"Respir Med"},{"key":"4819_CR74","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015578","author":"J Temmoku","year":"2019","unstructured":"Temmoku J, Sato S, Fujita Y et al (2019) Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis\/dermatomyositis. Medicine. https:\/\/doi.org\/10.1097\/MD.0000000000015578","journal-title":"Medicine"},{"key":"4819_CR75","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.rmed.2011.05.006","volume":"105","author":"K Tanizawa","year":"2011","unstructured":"Tanizawa K, Handa T, Nakashima R et al (2011) HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 105:1380\u20131387. https:\/\/doi.org\/10.1016\/j.rmed.2011.05.006","journal-title":"Respir Med"},{"key":"4819_CR76","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1093\/rheumatology\/keaa034","volume":"59","author":"Y Zuo","year":"2020","unstructured":"Zuo Y, Ye L, Liu M et al (2020) Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology 59:2829\u20132837. https:\/\/doi.org\/10.1093\/rheumatology\/keaa034","journal-title":"Rheumatology"},{"key":"4819_CR77","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","volume":"186","author":"Y Allenbach","year":"2016","unstructured":"Allenbach Y, Leroux G, Su\u00e1rez-Calvet X et al (2016) Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol 186:691\u2013700. https:\/\/doi.org\/10.1016\/j.ajpath.2015.11.010","journal-title":"Am J Pathol"},{"key":"4819_CR78","doi-asserted-by":"publisher","first-page":"15692","DOI":"10.1038\/s41598-020-72752-7","volume":"10","author":"R Wakura","year":"2020","unstructured":"Wakura R, Matsuda S, Kotani T et al (2020) The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease. Sci Rep 10:15692. https:\/\/doi.org\/10.1038\/s41598-020-72752-7","journal-title":"Sci Rep"},{"key":"4819_CR79","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10165-010-0371-x","volume":"21","author":"T Gono","year":"2011","unstructured":"Gono T, Kawaguchi Y, Ozeki E et al (2011) Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol 21:223\u2013227. https:\/\/doi.org\/10.1007\/s10165-010-0371-x","journal-title":"Mod Rheumatol"},{"key":"4819_CR80","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00296-019-04255-2","volume":"39","author":"T Nagashima","year":"2019","unstructured":"Nagashima T, Kamata Y, Iwamoto M et al (2019) Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis. Rheumatol Int 39:901\u2013909. https:\/\/doi.org\/10.1007\/s00296-019-04255-2","journal-title":"Rheumatol Int"},{"key":"4819_CR81","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/14397595.2018.1548918","volume":"29","author":"A Nishioka","year":"2019","unstructured":"Nishioka A, Tsunoda S, Abe T et al (2019) Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis. Mod Rheumatol 29:814\u2013820. https:\/\/doi.org\/10.1080\/14397595.2018.1548918","journal-title":"Mod Rheumatol"},{"key":"4819_CR82","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","volume":"32","author":"F Chen","year":"2012","unstructured":"Chen F, Wang D, Shu X et al (2012) Anti-MDA5 antibody is associated with A\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 32:3909\u20133915. https:\/\/doi.org\/10.1007\/s00296-011-2323-y","journal-title":"Rheumatol Int"},{"key":"4819_CR83","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3109\/14397595.2013.844390","volume":"24","author":"M Nara","year":"2014","unstructured":"Nara M, Komatsuda A, Omokawa A et al (2014) Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease. Mod Rheumatol 24:633\u2013636. https:\/\/doi.org\/10.3109\/14397595.2013.844390","journal-title":"Mod Rheumatol"},{"key":"4819_CR84","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0961203316651748","volume":"25","author":"R Nakashima","year":"2016","unstructured":"Nakashima R, Hosono Y, Mimori T (2016) Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus 25:925\u2013933. https:\/\/doi.org\/10.1177\/0961203316651748","journal-title":"Lupus"},{"key":"4819_CR85","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/1346-8138.15274","volume":"47","author":"KM Matsuda","year":"2020","unstructured":"Matsuda KM, Yoshizaki A, Kuzumi A et al (2020) Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. J Dermatol 47:483\u2013489. https:\/\/doi.org\/10.1111\/1346-8138.15274","journal-title":"J Dermatol"},{"key":"4819_CR86","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y et al (2020) Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation\u2013associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72:488\u2013498. https:\/\/doi.org\/10.1002\/art.41105","journal-title":"Arthritis Rheumatol"},{"key":"4819_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.235","author":"M Hayashi","year":"2017","unstructured":"Hayashi M, Aoki A, Asakawa K et al (2017) Cytokine profiles of amyopathic dermatomyositis with interstitial lung diseases treated with mycophenolate. Respirol Case Rep. https:\/\/doi.org\/10.1002\/rcr2.235","journal-title":"Respirol Case Rep"},{"key":"4819_CR88","doi-asserted-by":"publisher","first-page":"105983","DOI":"10.1016\/j.rmed.2020.105983","volume":"172","author":"M-M Mao","year":"2020","unstructured":"Mao M-M, Xia S, Guo B-P et al (2020) Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis\/dermatomyositis associated ILD. Respir Med 172:105983. https:\/\/doi.org\/10.1016\/j.rmed.2020.105983","journal-title":"Respir Med"},{"key":"4819_CR89","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001191","author":"J Mrosak","year":"2019","unstructured":"Mrosak J, Banasiak K, Edelheit B et al (2019) Polymyxin-B hemoperfusion as a novel treatment for rapidly progressive interstitial lung disease in a pediatric patient diagnosed with anti-MDA5 juvenile dermatomyositis. J Clin Rheumatol. https:\/\/doi.org\/10.1097\/RHU.0000000000001191","journal-title":"J Clin Rheumatol"},{"key":"4819_CR90","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","volume":"59","author":"Y Abe","year":"2020","unstructured":"Abe Y, Kusaoi M, Tada K et al (2020) Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology 59:767\u2013771. https:\/\/doi.org\/10.1093\/rheumatology\/kez357","journal-title":"Rheumatology"},{"key":"4819_CR91","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa123","author":"M Shirakashi","year":"2020","unstructured":"Shirakashi M, Nakashima R, Tsuji H et al (2020) Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keaa123","journal-title":"Rheumatology"},{"key":"4819_CR92","unstructured":"T S, M M, Y M, et al (2020) Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: a case series. J Clinical Apher. https:\/\/pubmed.ncbi.nlm.nih.gov\/32823371\/. Accessed 26 Oct 2020"},{"key":"4819_CR93","doi-asserted-by":"publisher","first-page":"e21943","DOI":"10.1097\/MD.0000000000021943","volume":"99","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa Y, Kasuya T, Fujiwara M, Kita Y (2020) Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report. Medicine 99:e21943. https:\/\/doi.org\/10.1097\/MD.0000000000021943","journal-title":"Medicine"},{"key":"4819_CR94","first-page":"904","volume":"33","author":"M Groh","year":"2015","unstructured":"Groh M, Rogowska K, Monsarrat O et al (2015) Interleukin-1 receptor antagonist for refractory anti-MDA5 clinically amyopathic dermatomyopathy. Clin Exp Rheumatol 33:904\u2013905","journal-title":"Clin Exp Rheumatol"},{"key":"4819_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/srep33226","author":"T Li","year":"2016","unstructured":"Li T, Guo L, Chen Z et al (2016) Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep. https:\/\/doi.org\/10.1038\/srep33226","journal-title":"Sci Rep"},{"key":"4819_CR96","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00296-019-04398-2","volume":"39","author":"K Huang","year":"2019","unstructured":"Huang K, Vinik O, Shojania K et al (2019) Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int 39:1971\u20131981. https:\/\/doi.org\/10.1007\/s00296-019-04398-2","journal-title":"Rheumatol Int"},{"key":"4819_CR97","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","volume":"50","author":"F Romero-Bueno","year":"2020","unstructured":"Romero-Bueno F, Diaz Del Campo P, Trallero-Aragu\u00e1s E et al (2020) Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 50:776\u2013790. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.03.007","journal-title":"Semin Arthritis Rheum"},{"key":"4819_CR98","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1097\/RHU.0000000000001114","volume":"26","author":"J Jeter","year":"2020","unstructured":"Jeter J, Wolf EG, Richards M, Hill E (2020) Successful treatment of anti-MDA5 dermatomyositis associated cutaneous digital pulp ulcerations with hyperbaric oxygen therapy. J Clin Rheumatol 26:e266\u2013e267. https:\/\/doi.org\/10.1097\/RHU.0000000000001114","journal-title":"J Clin Rheumatol"},{"key":"4819_CR99","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1740400","author":"K Yamaguchi","year":"2020","unstructured":"Yamaguchi K, Yamaguchi A, Onuki Y et al (2020) Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age. Mod Rheumatol. https:\/\/doi.org\/10.1080\/14397595.2020.1740400","journal-title":"Mod Rheumatol"},{"key":"4819_CR100","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","volume":"57","author":"S Sato","year":"2018","unstructured":"Sato S, Masui K, Nishina N et al (2018) Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology 57:1212\u20131221. https:\/\/doi.org\/10.1093\/rheumatology\/key060","journal-title":"Rheumatology"},{"key":"4819_CR101","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","volume":"158","author":"X Lian","year":"2020","unstructured":"Lian X, Zou J, Guo Q et al (2020) Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model. Chest 158:1535\u20131545. https:\/\/doi.org\/10.1016\/j.chest.2020.04.057","journal-title":"Chest"},{"key":"4819_CR102","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Sato S, Kawaguchi Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51:1563\u20131570. https:\/\/doi.org\/10.1093\/rheumatology\/kes102","journal-title":"Rheumatology"},{"key":"4819_CR103","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/acr.22728","volume":"68","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia S, Oddis CV, Sato S et al (2016) Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in us patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res 68:689\u2013694. https:\/\/doi.org\/10.1002\/acr.22728","journal-title":"Arthritis Care Res"},{"key":"4819_CR104","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab001","author":"P Mehta","year":"2021","unstructured":"Mehta P, Agarwal V, Gupta L (2021) High early mortality in idiopathic inflammatory myopathies: results from the inception cohort at a tertiary care center in northern India. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keab001","journal-title":"Rheumatology"},{"key":"4819_CR105","doi-asserted-by":"publisher","first-page":"R138","DOI":"10.1186\/ar4600","volume":"16","author":"SL Tansley","year":"2014","unstructured":"Tansley SL, Betteridge ZE, Gunawardena H et al (2014) Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 16:R138. https:\/\/doi.org\/10.1186\/ar4600","journal-title":"Arthritis Res Ther"},{"key":"4819_CR106","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa429","author":"G Mamyrova","year":"2020","unstructured":"Mamyrova G, Kishi T, Shi M et al (2020) Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in north America. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keaa429","journal-title":"Rheumatology"},{"key":"4819_CR107","doi-asserted-by":"publisher","first-page":"e22978","DOI":"10.1002\/jcla.22978","volume":"33","author":"Y Ye","year":"2019","unstructured":"Ye Y, Fu Q, Wang R et al (2019) Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease. J Clin Lab Anal 33:e22978. https:\/\/doi.org\/10.1002\/jcla.22978","journal-title":"J Clin Lab Anal"},{"key":"4819_CR108","doi-asserted-by":"publisher","first-page":"e0234523","DOI":"10.1371\/journal.pone.0234523","volume":"15","author":"S Kaieda","year":"2020","unstructured":"Kaieda S, Gono T, Masui K et al (2020) Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease. PLoS ONE 15:e0234523. https:\/\/doi.org\/10.1371\/journal.pone.0234523","journal-title":"PLoS ONE"},{"key":"4819_CR109","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/cei.13404","volume":"199","author":"Q-L Peng","year":"2020","unstructured":"Peng Q-L, Zhang Y-M, Liang L et al (2020) A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis. Clin Exp Immunol 199:314\u2013325. https:\/\/doi.org\/10.1111\/cei.13404","journal-title":"Clin Exp Immunol"},{"key":"4819_CR110","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/rheumatology\/kez185","volume":"58","author":"Y Horiike","year":"2019","unstructured":"Horiike Y, Suzuki Y, Fujisawa T et al (2019) Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. Rheumatology 58:2143\u20132152. https:\/\/doi.org\/10.1093\/rheumatology\/kez185","journal-title":"Rheumatology"},{"key":"4819_CR111","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/1346-8138.15117","volume":"46","author":"T Matsushita","year":"2019","unstructured":"Matsushita T, Kobayashi T, Kano M et al (2019) Elevated serum B-cell activating factor levels in patients with dermatomyositis: association with interstitial lung disease. J Dermatol 46:1190\u20131196. https:\/\/doi.org\/10.1111\/1346-8138.15117","journal-title":"J Dermatol"},{"key":"4819_CR112","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/bjd.16917","volume":"180","author":"SH Zhang","year":"2019","unstructured":"Zhang SH, Zhao Y, Xie QB et al (2019) Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis. Br J Dermatol 180:1090\u20131098. https:\/\/doi.org\/10.1111\/bjd.16917","journal-title":"Br J Dermatol"},{"key":"4819_CR113","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10067-012-2142-x","volume":"32","author":"Y Muro","year":"2013","unstructured":"Muro Y, Sugiura K, Akiyama M (2013) Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheumatol 32:395\u2013398. https:\/\/doi.org\/10.1007\/s10067-012-2142-x","journal-title":"Clin Rheumatol"},{"key":"4819_CR114","first-page":"1719","volume":"32","author":"H Kameda","year":"2005","unstructured":"Kameda H, Nagasawa H, Ogawa H et al (2005) Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32:1719\u20131726","journal-title":"J Rheumatol"},{"key":"4819_CR115","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","volume":"37","author":"H So","year":"2018","unstructured":"So H, Wong VTL, Lao VWN et al (2018) Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol 37:1983\u20131989. https:\/\/doi.org\/10.1007\/s10067-018-4122-2","journal-title":"Clin Rheumatol"},{"key":"4819_CR116","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2169\/internalmedicine.56.7956","volume":"56","author":"K Tokunaga","year":"2017","unstructured":"Tokunaga K, Hagino N (2017) Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a report of 3 cases in Japan. Intern Med 56:1399\u20131403. https:\/\/doi.org\/10.2169\/internalmedicine.56.7956","journal-title":"Intern Med"},{"key":"4819_CR117","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","volume":"73","author":"J Zou","year":"2014","unstructured":"Zou J, Li T, Huang X et al (2014) Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis 73:1591\u20131593. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205278","journal-title":"Ann Rheum Dis"},{"key":"4819_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21833","author":"T Saito","year":"2020","unstructured":"Saito T, Mizobuchi M, Miwa Y et al (2020) Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: a case series. J Clin Apher. https:\/\/doi.org\/10.1002\/jca.21833","journal-title":"J Clin Apher"},{"key":"4819_CR119","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12890-017-0479-2","volume":"17","author":"H Okabayashi","year":"2017","unstructured":"Okabayashi H, Ichiyasu H, Hirooka S et al (2017) Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias. BMC Pulm Med 17:134. https:\/\/doi.org\/10.1186\/s12890-017-0479-2","journal-title":"BMC Pulm Med"},{"key":"4819_CR120","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.rmed.2015.07.004","volume":"109","author":"T Takada","year":"2015","unstructured":"Takada T, Aoki A, Asakawa K et al (2015) Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140\/MDA5 antibody positive amyopathic dermatomyositis. Respir Med 109:1174\u20131180. https:\/\/doi.org\/10.1016\/j.rmed.2015.07.004","journal-title":"Respir Med"},{"key":"4819_CR121","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.rmcr.2016.11.015","volume":"20","author":"H Ichiyasu","year":"2017","unstructured":"Ichiyasu H, Sakamoto Y, Yoshida C et al (2017) Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy. Respir Med Case Rep 20:51\u201354. https:\/\/doi.org\/10.1016\/j.rmcr.2016.11.015","journal-title":"Respir Med Case Rep"},{"key":"4819_CR122","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1378\/chest.13-0186","volume":"144","author":"A Teruya","year":"2013","unstructured":"Teruya A, Kawamura K, Ichikado K et al (2013) Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140\/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest 144:1934\u20131936. https:\/\/doi.org\/10.1378\/chest.13-0186","journal-title":"Chest"},{"key":"4819_CR123","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y et al (2018) Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology 57:2114\u20132119. https:\/\/doi.org\/10.1093\/rheumatology\/key188","journal-title":"Rheumatology"},{"key":"4819_CR124","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13613-018-0433-3","volume":"8","author":"C Vuillard","year":"2018","unstructured":"Vuillard C, Pineton de Chambrun M, de Prost N et al (2018) Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study. Ann Intensive Care 8:87. https:\/\/doi.org\/10.1186\/s13613-018-0433-3","journal-title":"Ann Intensive Care"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04819-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04819-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04819-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T15:13:31Z","timestamp":1619536411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04819-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":124,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4819"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04819-1","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,27]]},"assertion":[{"value":"1 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PM and LG report no conflicts of interest\/competing interests. PMM has received consulting\/speaker\u2019s fees from Abbvie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}